Subscribe

Suven Life Sciences Limited (SUVEN.NS)

INR268.25 +5.10 (+1.94%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address 8-2-334, SDE Serene Chambers 500034
Hyderabad, IN
CEO Venkateswarlu Jasti
Website suven.com
IPO 2003-10-24
ISIN INE495B01038

Explore sections of this company profile

Also trades on Bombay Stock Exchange · SUVEN.BO (INR) National Stock Exchange of India · SUVEN.NS (INR)
Description

Suven Life Sciences Limited operates as a clinical-stage biopharmaceutical enterprise dedicated to the identification, progression, and commercialization of innovative therapeutic solutions. Its primary focus lies in addressing neurodegenerative conditions across key markets including India, the United States, Europe, and other international territories. The company's core activities revolve around the discovery and subsequent development of new chemical entities (NCEs) specifically targeting disorders of the central nervous system (CNS). Among its promising pipeline assets are SUVN-502, intended for Alzheimer's disease and associated neuropsychiatric manifestations; SUVN-G3031, a potent and selective inverse agonist of the histamine H3 receptor, aimed at sleep and cognitive impairments; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist designed to alleviate depressive disorders. Further advancing its portfolio, Suven is also working on SUVN-D4010, a potent, selective, orally bioavailable, and brain-penetrant partial agonist of the 5-HT4 receptor for cognitive dysfunctions; SUVN-I6107, addressing cognitive issues and schizophrenia; SUVN-M8036 for various psychiatric ailments; and SUVN-D1044, targeting gastrointestinal conditions. Established in 1989, the company is based in Hyderabad, India. It adopted its current name, Suven Life Sciences Limited, in 2003, having previously operated as Suven Pharmaceuticals Pvt. Ltd. Jasti Property and Equity Holdings Private Limited holds a controlling interest in Suven Life Sciences Limited, making it a subsidiary.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
INR268.25 +5.10 (+1.94%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.84
Float Shares
63.70M
Free Float %
28.4%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.17% +30.23% +27.98% +78.04% +52.68% +61.77% +30.80% +371.89% +197.12% +2,261.55% +28,041.58%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
268.25
DCF (Unlevered) 11.78 -95.6%
DCF (Levered) 10.53 -96.1%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2025-08 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
109.68
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +6.9% ★ Q1'26: +3.6% (vs Q1'25)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    -64.8% Q1'26: -0.5% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    -4,330.1% Q1'26: -6,941.5% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    -4,077.7% Q1'26: -3,435.0% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    -322.4% Q1'26: -232.1% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +4.3% Q1'26: +3.3% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    -0.06× Q1'26: -0.08× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.40) × ERP
WACC = 100% × Ke + 0% × Kd (4.2%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 11.76 Current price: 268.25
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Mar 2011
actual 		Mar 2013
actual 		Mar 2014
actual 		Mar 2015
actual 		Mar 2016
actual 		Mar 2017
actual 		Mar 2018
actual 		Mar 2019
actual 		Mar 2020
actual 		Mar 2021
actual 		Mar 2022
actual 		Mar 2023
actual 		Mar 2024
actual 		Mar 2025
actual 		Mar 2026
1 Rev. Ana.
1 EPS Ana. 		Mar 2027
1 Rev. Ana.
1 EPS Ana. 		Mar 2028
1 Rev. Ana.
1 EPS Ana. 		Mar 2029
1 Rev. Ana.
1 EPS Ana. 		Mar 2030
1 Rev. Ana.
1 EPS Ana. 		Mar 2031
1 Rev. Ana.
1 EPS Ana.
Revenue
1.50B
est: 1.59B (-5.2%)
2.58B
est: 2.63B (-2.0%)
5.10B
est: 5.23B (-2.5%)
5.21B
est: 5.32B (-2.1%)
5.00B
est: 4.76B (+4.9%)
5.44B
est: 5.28B (+2.9%)
6.13B
est: 6.11B (+0.2%)
6.45B
est: 5.84B (+10.4%)
144.15M
est: 8.56B (-98.3%)
134.78M
est: 9.93B (-98.6%)
118.44M
est: 11.24B (-98.9%)
135.39M
est: 12.90B (-99.0%)
116.93M
est: 12.50B (-99.1%)
66.56M
est: 4.76B (-98.6%)
4.76B
4.76B – 4.76B
+0.0% YoY
5.28B
5.28B – 5.28B
+11.0% YoY
6.11B
6.11B – 6.11B
+15.7% YoY
5.84B
5.84B – 5.84B
-4.4% YoY
8.56B
8.56B – 8.56B
+46.5% YoY
9.93B
9.93B – 9.93B
+16.0% YoY
EBITDA
-1.39B
est: -1.59B (+12.3%)
559.97M
est: -2.58B (+121.7%)
2.22B
est: -5.13B (+143.3%)
1.82B
est: 2.10B (-13.4%)
1.27B
est: 1.66B (-23.1%)
1.57B
est: 1.54B (+1.6%)
2.25B
est: 1.86B (+20.7%)
162.67M
est: 2.52B (-93.5%)
-1.02B
est: 2.71B (-137.5%)
-721.87M
est: -1.19B (+39.3%)
-1.17B
est: -6.35B (+81.6%)
-1.11B
est: -1.63B (+31.7%)
-992.78M
est: -12.50B (+92.1%)
-1.55B
est: -4.76B (+67.5%)
-4.76B
-4.76B – -4.76B
+0.0% YoY
-5.28B
-5.28B – -5.28B
-11.0% YoY
-6.11B
-6.11B – -6.11B
-15.7% YoY
-5.84B
-5.84B – -5.84B
+4.4% YoY
-8.56B
-8.56B – -8.56B
-46.5% YoY
-9.93B
-9.93B – -9.93B
-16.0% YoY
EBIT
93.60M
est: -1.59B (+105.9%)
452.68M
est: -2.58B (+117.5%)
2.09B
est: 977.61M (+113.7%)
1.56B
est: 2.12B (-26.4%)
1.02B
est: 1.35B (-24.9%)
1.27B
est: 951.63M (+33.3%)
1.98B
est: 1.22B (+62.9%)
13.57M
est: 1.85B (-99.3%)
-1.06B
est: 1.82B (-158.1%)
-765.33M
est: -1.38B (+44.6%)
-1.21B
est: -11.02B (+89.0%)
-1.18B
est: -1.89B (+37.8%)
-1.06B
est: -12.50B (+91.5%)
-1.61B
est: -4.76B (+66.2%)
-4.76B
-4.76B – -4.76B
+0.0% YoY
-5.28B
-5.28B – -5.28B
-11.0% YoY
-6.11B
-6.11B – -6.11B
-15.7% YoY
-5.84B
-5.84B – -5.84B
+4.4% YoY
-8.56B
-8.56B – -8.56B
-46.5% YoY
-9.93B
-9.93B – -9.93B
-16.0% YoY
Net Income
104.00M
est: 247.59M (-58.0%)
308.40M
est: 590.01M (-47.7%)
1.44B
est: 2.83B (-49.1%)
1.09B
est: 1.45B (-25.2%)
667.39M
est: 995.41M (-33.0%)
871.87M
est: 811.14M (+7.5%)
1.24B
est: 975.34M (+26.8%)
869.43M
est: 1.30B (-32.9%)
-942.18M
est: 1.14B (-182.3%)
-721.51M
est: -1.09B (+33.7%)
-1.22B
est: 7.61B (-116.0%)
-1.18B
est: -1.49B (+20.7%)
-1.05B
est: 2.80B (-137.6%)
-1.61B
est: 97.33M (-1,751.6%)
97.33M
97.33M – 97.33M
+0.0% YoY
110.71M
110.71M – 110.71M
+13.8% YoY
148.02M
148.02M – 148.02M
+33.7% YoY
131.93M
131.93M – 131.93M
-10.9% YoY
156.81M
156.81M – 156.81M
+18.9% YoY
177.08M
177.08M – 177.08M
+12.9% YoY
SGA
118.28M
est: 1.64B (-92.8%)
278.43M
est: 2.66B (-89.5%)
207.29M
est: 842.18M (-75.4%)
237.12M
est: 523.93M (-54.7%)
115.54M
est: 678.12M (-83.0%)
563.37M
est: 943.64M (-40.3%)
154.17M
est: 1.12B (-86.3%)
205.50M
est: 1.23B (-83.3%)
9.76M
est: 1.72B (-99.4%)
185.36M
est: 289.24M (-35.9%)
210.21M
est: 11.36B (-98.1%)
186.21M
est: 396.43M (-53.0%)
27.11M
est: 12.89B (-99.8%)
26.42M
est: 4.91B (-99.5%)
4.91B
4.91B – 4.91B
+0.0% YoY
5.45B
5.45B – 5.45B
+11.0% YoY
6.30B
6.30B – 6.30B
+15.7% YoY
6.02B
6.02B – 6.02B
-4.4% YoY
8.82B
8.82B – 8.82B
+46.5% YoY
10.23B
10.23B – 10.23B
+16.0% YoY
EPS
0.81
est: 1.13 (-28.5%)
2.43
est: 2.74 (-11.3%)
11.37
est: 13.15 (-13.6%)
8.33
est: 0.56 (+1,384.7%)
5.17
est: 0.45 (+1,060.8%)
6.31
est: 0.51 (+1,145.5%)
8.95
est: 0.68 (+1,221.3%)
5.51
est: 0.60 (+812.6%)
-5.97
est: 0.72 (-932.0%)
-4.57
est: 0.81 (-664.0%)
-7.73
est: 35.33 (-121.9%)
-7.50
est: 61.12 (-112.3%)
-4.82
est: 12.80 (-137.7%)
-7.36
est: 0.45 (-1,752.5%)
0.45
0.45 – 0.45
+0.0% YoY
0.51
0.51 – 0.51
+13.8% YoY
0.68
0.68 – 0.68
+33.7% YoY
0.60
0.60 – 0.60
-10.9% YoY
0.72
0.72 – 0.72
+18.9% YoY
0.81
0.81 – 0.81
+12.9% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-20 C 2/5 3/5 1/5 1/5 3/5 1/5 2/5
2026-05-19 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-18 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-15 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-14 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-13 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-12 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-11 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-08 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-07 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-06 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-05 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-05-04 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-30 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-29 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-28 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-27 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-24 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-23 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-22 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-21 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-20 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-17 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5
2026-04-16 D+ 1/5 1/5 1/5 1/5 1/5 1/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-1.07B
OE per share TTM
-4.82
Owner's Yield
-1.76%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
86.1%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-205.8K
Shares Outstanding
224.01M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Sudharani Jasti Whole-Time Director 5M female
Kalyani Jasti President of US Operations — female
Mohan Kumar Chief Financial Officer — male
N. V. S. Ramakrishna President & Chief Scientific Officer — —
Sangeetha Laxmi Kandari Company Secretary & Compliance Officer — female
Venkateswarlu Jasti Chief Executive Officer, MD & Executive Chairman — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic